Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;28(7):671-8.
doi: 10.1038/nbt0710-671.

Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India

Swathi Padmanabhan  1 , Tahir Amin, Bhaven Sampat, Robert Cook-Deegan, Subhashini Chandrasekharan
Affiliations

Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India

Swathi Padmanabhan et al. Nat Biotechnol. 2010 Jul.

Erratum in

  • Nat Biotechnol. 2012 Feb;30(2):193
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Impact of patents on manufacturing, sale, and/or export of “bio-similar” HPV vaccines by developing country vaccine manufacturers
Patents existing in the country of the manufacturer that claim the “composition of matter” of necessary antigens (e.g. nucleic acid and/or amino acid sequences of the L1 proteins) or the vaccine itself (e.g. VLPs made of L1 antigens) would prevent DCVMs from developing and selling vaccines in their country without a license from the patent owner. If, however, patents only claim specific methods or processes for producing the vaccine, manufacturers may have freedom to operate if they use alternate processes to “work around” those patents. Patents granted in jurisdictions outside the manufacturing country – especially in potential export markets – may also affect DCVM vaccine development plans. Manufacturers exporting vaccinesto these countries would infringe patents if their vaccines embodied the compositions or processes protected by such patents. However, if vaccines had different formulations or were developed by using alternate processes, they could still be sold in the importing country.
See this image and copyright information in PMC

References

    1. Agosti JM, et al. NEJM. 2007;356:1908–1910. - PubMed
    1. Gakidou E, et al. PLoS Med. 2008;17:e132. - PMC - PubMed
    1. Lowy DR, et al. J. Clin. Invest. 2006;116:1167–1173. - PMC - PubMed
    1. CDC negotiated price for Gardasil. [accessed 20 January 2010]; http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm.
    1. Making Cervical Cancer Vaccines Widely Available in Developing Countries: Cost and Financing Issues. [accessed 20 January 2010]; screening.iarc.fr/doc/IAVI_PATH_HPV_financing_brief.pdf.

Publication types

MeSH terms

Substances